Mediwound, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Okunewitch from Maxim Group maintained a Buy rating on the stock and has a $30.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Michael Okunewitch’s rating is based on several promising developments within MediWound’s pipeline and financial outlook. The company has reported a revenue of $5.7 million for the second quarter of 2025, with sufficient cash reserves projected to last into 2027, providing a stable financial foundation. Additionally, MediWound’s guidance for 2025 anticipates revenue of at least $24 million, indicating growth potential.
Furthermore, the ongoing Phase 3 VALUE study for EscharEx, targeting venous leg ulcers, is progressing with an interim analysis expected in mid-2026. EscharEx is positioned as a disruptive technology in the chronic wound care market, with a significant market opportunity estimated at $2.5 billion. The planned head-to-head study against the current market leader, Santyl, and the upcoming Phase 2/3 study for diabetic foot ulcers, underscore the potential for EscharEx to capture a substantial market share. These factors collectively contribute to Okunewitch’s Buy rating for MediWound.